Pharmacokinetic-Pharmacodynamic Modelling of Adverse Effects of Nitrendipine I. Locatelli, I. Grabnar, A.Belič, A. Mrhar, R. Karba University of Ljubljana.

Slides:



Advertisements
Similar presentations
Clinical Pharmacokinetics
Advertisements

The half-life OCT 2010.
Animal Model PK/PD: A Tool for Drug Development
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
Population PK/PD analysis of the bactericidal activity of sutezolid and its major metabolite against intracellular Mtb in whole blood cultures of TB patients.
Pharmacotherapy in the Elderly Judy Wong
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Gokaraju Rangaraju College of Pharmacy
University of Jordan-Faculty of Pharmacy
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Nonlinear Pharmacokinetics
Concepts and Applications of Pharmacokinetics
RESEARCH Lymphatic Targeting of Tenofovir; Intracellular Pharmacokinetics and Viral Dynamics Arnold Fridland, Ph.D, William Lee, Ph.D. Gilead Sciences,
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
1 QT Evaluation Studies: Pharmacometric Considerations Leslie Kenna, Peter Lee and Yaning Wang Office of Clinical Pharmacology and Biopharmaceutics CDER/FDA.
Bioavailability Dr Mohammad Issa.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Logistic and Nonlinear Regression Logistic Regression - Dichotomous Response variable and numeric and/or categorical explanatory variable(s) –Goal: Model.
PHARMACOKINETIC MODELS
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
EFFECTS OF DULOXETINE ON THE PHARMACOKINETICS OF NEBIVOLOL IN HEALTHY VOLUNTEERS Corina Briciu 1, Maria Neag 2, Dana Muntean 3, Corina Bocsan 2, Anca Buzoianu.
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Biopharmaceutics refers to the relationship of the:
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
Modeling Data: Methods and Examples Arthur G. Roberts.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Clinical Pharmacokinetics of Carbamazepine
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
CHAPTER 7 ABSORPTION KINETICS.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Study Aids Anki Flash cards – Content that you need to know for the tests. MS Excel sheet with Calculations.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
PHT 415 BASIC PHARMACOKINETICS
The General Concepts of Pharmacokinetics and Pharmacodynamics
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
415 PHT Plasma Level – Time Curve
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
IPCP Core C Activities Aprepitant Dose-exposure Relationship in the Monkey Jeffrey S. Barrett, Ph.D., FCP The Children’s Hospital of Philadelphia Division.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
MS WinNonLin Project 9/28/15: PK Modeling I project due today.
Drug Response Relationships
Applications of Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Pharmacokinetics.
Clinical Pharmacokinetics
Clinical Pharmacokinetics
1 Concentration-time curve
Therapeutic Drug Monitoring chapter 1 part 1
Biopharmaceutics and pharmacokinetic by: Anjam Hama A. M. Sc
Presentation transcript:

Pharmacokinetic-Pharmacodynamic Modelling of Adverse Effects of Nitrendipine I. Locatelli, I. Grabnar, A.Belič, A. Mrhar, R. Karba University of Ljubljana Ljubljana, Slovenia 4 th MATHMOD, Vienna, 2003

PK-PD Modelling Pharmacokinetics: – time courses of drug concentration in body fluids (mainly blood plasma) resulting from a drug dose, – drug (metabolites) concentration determination, problems with biological matix, LOQ, accuracy – whole body influence, – steady state or nonsteady state.

PK-PD Modelling Pharmacodynamics: – effects resulting from a certain drug concentration Types of drug effects: reversibleirreversible – direct (rapid,slow)- chemotherapy – indirect:- enzyme inactivation transduction processes, enzyme induction Effect measurements should be: sensitive, reproducible, objective and meaningful.

PK-PD Modelling Goals of modellig: – optimization of drug therapy, – improvement of drug efficacy and safety, – estimating inaccessible system variables, – predicting system response under new conditions. PK models (one-, two- compartment,...) PD models (Hill function and its derivatives) Link models (direct vs. indirect link, direct vs. indirect response... )

Aims Safety aspect of an antihypertensive drug nitrendipine Exploration of the relationship between its plasma concentration and occurrence of adverse effects Criteria for the design of optimal drug dosage regimen and for selecting individuals with high probability for adverse drug reactions

Nitrendipine Potent calcium channels blocker Vasodilatation and decrease in peripheral vascular resistance, subsequent reduction of blood pressure Highly variable PK due to extensive first-pass metabolism (F = 16%) and high plasma protein binding (98 %) PK is linear, no plasma accumulation after once daily regimen Mild, but frequent adverse effects: – Headache (vasodilatation in the brain) – Flushing, palpitations, ankle oedema, dizziness (peripheral vasodilatation and increased baroreflex feedback control)

Database Replicated 2 x 2 cross over bioequivalence study, 40 male volunteers (18-30 yrs.), single dose 20 mg 16 blood samples in each period up to 48 hrs. after drug administration During the period of 48 hrs. volunteers were observed for eventual occurrence of adverse effects – recording of onset time and duration Adverse effects occurred in 26 out of 160 drug applications: – Headache: 24 (average duration 3.3 ± 2.7 hrs.) – Flush: 4 – Vertigo: 1

PK/PD analysis – 1. STEP (PK) Exploration of nitrendipine pharmacokinetics: compartmental analysis of individual concentration-time profiles (160 cases): - One/two compartment model with first order absorption and elimination, with or without lagtime - Model evaluation: Akaike Criterion (AIC), Schwartz Criterion (SC), parameters’ coeficient of variation (CV par )

PK model Two compartment model with lagtime: Two diferential equations:

PK model Two compartment model with lagtime: Overall equation - integrated: Estimated PK parameters: V C /F, k A, k EL, k 12, k 21 and t LAG WinNonLin - software

Compartmental PK models Four linear compartmental models PK modelV C /F [L]k A [h -1 ]k EL [h -1 ]k 12 [h -1 ]k 21 [h -1 ]t LAG [h] one- compartment 2200    0.20 /// one- compartment with t LAG 2360    0.28 // 0.54  0.43 two- compartment 1850      0.24 / two compartment with t LAG 2020       0.50 AIC

PK/PD analysis – 2. STEP (PD) Exploration of Pharmacodynamics: Adverse effect-time courses (24 cases only) Fixed effect (or logistic) pharmacodynamic model: - p – probability that adverse effect will happen - EC 50 – concentration at which the probability of response (p) is 50%

PK/PD analysis – 3.STEP (LINK)

Indirect link model (hysteresis): – Direct response model – Soft link PK/PD model – Time independent link model Simplifications:

PK/PD model Additonal parameters estimated: k E0, EC 50, n

PK/PD model Two-compartment PK model with lagtime Fixed effect PD model Indirect link model (to minimaze the hysteresis) Model equation:

PK/PD model - case 1

n’k EO [h -1 ]ec 50 [ng/ml] WinNonLin   1.9 EXCEL   2.2 PK/PD parameter estimation

Nonlinear regression (SPSS) EC50 = 6.62 ± 0.22 ng/ml (glavobol je prisoten) EC50 = 39.8 ± 2.5 ng/ml (glavobol ni prisoten)

Zaključek Na podanih eksperimentalnih podatkih dvoprostorni model s t LAG najbolje opisuje potek plazemskih koncentracij nitrendipina. Aplikacije s stranskim učinkom imajo višjo hitrost in večji obseg absorpcije kot tiste brez stranskega učinka (primerjava povprečnih vrednosti za k A, t MAX, C MAX, AUC). subpopulacija skupine z glavobolom ima nižje vrednosti EC 50 (večja občutljivost) kot celotna populacija Tako FK parametri (povečana koncentracija nitrendipina) kot FD parametri (povečana občutljivost na nitrendipin) vplivajo na pojav glavobola pri nitrendipinu

Conclusions An increased exposure as well as an increased sensitivity to nitrendipine at the site of action were found to expand the probability for side effects. The developed methodology could supply useful criteria for the design of optimal drug dosage regimen, moreover it offers possibility for selecting individuals with high probability for adverse drug reactions.